122 related articles for article (PubMed ID: 20491610)
1. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population.
Alemayehu B; Buysman E; Parry D; Becker L; Nathan F
J Med Econ; 2010; 13(2):351-61. PubMed ID: 20491610
[TBL] [Abstract][Full Text] [Related]
2. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population.
Amonkar MM; Chastek B; Samant N; Teitelbaum A
J Med Econ; 2011; 14(4):421-32. PubMed ID: 21619455
[TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer.
Crawford ED; Black L; Eaddy M; Kruep EJ
Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):162-7. PubMed ID: 20125121
[TBL] [Abstract][Full Text] [Related]
5. The direct medical costs of Huntington's disease by stage. A retrospective commercial and Medicaid claims data analysis.
Divino V; Dekoven M; Warner JH; Giuliano J; Anderson KE; Langbehn D; Lee WC
J Med Econ; 2013 Aug; 16(8):1043-50. PubMed ID: 23789925
[TBL] [Abstract][Full Text] [Related]
6. Healthcare resource use in advanced prostate cancer patients treated with docetaxel.
Mehra M; Wu Y; Dhawan R
J Med Econ; 2012; 15(5):836-43. PubMed ID: 22463616
[TBL] [Abstract][Full Text] [Related]
7. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
8. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
[TBL] [Abstract][Full Text] [Related]
9. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
Wu B; Li SS; Song J; Pericone CD; Behl AS; Dawson NA
J Med Econ; 2020 Jan; 23(1):54-63. PubMed ID: 31589086
[No Abstract] [Full Text] [Related]
10. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
11. Medicare patient experience with vagus nerve stimulation for treatment-resistant depression.
Feldman RL; Dunner DL; Muller JS; Stone DA
J Med Econ; 2013; 16(1):62-74. PubMed ID: 22954061
[TBL] [Abstract][Full Text] [Related]
12. Cost of fractures commonly associated with osteoporosis in a managed-care population.
Christensen L; Iqbal S; Macarios D; Badamgarav E; Harley C
J Med Econ; 2010; 13(2):302-13. PubMed ID: 20482324
[TBL] [Abstract][Full Text] [Related]
13. The economic burden of prostate cancer, California, 1998.
Max W; Rice DP; Sung HY; Michel M; Breuer W; Zhang X
Cancer; 2002 Jun; 94(11):2906-13. PubMed ID: 12115378
[TBL] [Abstract][Full Text] [Related]
14. The cost of treating skeletal-related events in patients with prostate cancer.
Lage MJ; Barber BL; Harrison DJ; Jun S
Am J Manag Care; 2008 May; 14(5):317-22. PubMed ID: 18471035
[TBL] [Abstract][Full Text] [Related]
15. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
16. Patterns of healthcare utilization and cost in patients with newly diagnosed fibromyalgia.
Berger A; Sadosky A; Dukes EM; Edelsberg J; Zlateva G; Oster G
Am J Manag Care; 2010 May; 16(5 Suppl):S126-37. PubMed ID: 20586521
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database.
Sadetsky N; Elkin EP; Latini DM; DuChane J; Carroll PR;
Prostate Cancer Prostatic Dis; 2008; 11(3):280-7. PubMed ID: 17893700
[TBL] [Abstract][Full Text] [Related]
18. Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor.
Sadetsky N; Lubeck DP; Pasta DJ; Latini DM; DuChane J; Carroll PR
BJU Int; 2008 Mar; 101(6):691-7. PubMed ID: 18291018
[TBL] [Abstract][Full Text] [Related]
19. The burden of depression in prostate cancer.
Jayadevappa R; Malkowicz SB; Chhatre S; Johnson JC; Gallo JJ
Psychooncology; 2012 Dec; 21(12):1338-45. PubMed ID: 21837637
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000.
McNaughton-Collins M; Walker-Corkery E; Barry MJ
J Natl Cancer Inst Monogr; 2004; (33):78-101. PubMed ID: 15504921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
